Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.

Abstract

The advent of chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of several hematological malignancies. Although the initial benefit was mainly observed in aggressive leukemias and lymphomas, recent data have resulted in the approval of multiple CAR-T therapies in indolent lymphomas, with ongoing research showing great promise for further improvements and therapeutic optimizations. In this article, we review the published data and approved therapies for CAR-T cell therapy for indolent lymphomas focusing on mantle cell lymphoma and follicular lymphoma while describing the work in chronic lymphocytic leukemia and future strategies.

• Authors: Parth S Shah, Caron A Jacobson
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 37 Issue 6 Pg. 1077-1088 (Dec 2023) ISSN: 1558-1977 [Electronic] United States
• PMID: 37659889 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.